Autoantibodies Prevalence During Checkpoint Inhibitor Treatment
Active, not recruiting
- Conditions
- Autoimmune Adverse Effects of Anti-neoplasic Drug
- Registration Number
- NCT04220034
- Lead Sponsor
- CHU de Reims
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Inclusion Criteria:<br><br> - patients receiving check point inhibitor for a neoplasic disease in a center that<br> participates to the study during the inclusion period<br><br> - patients who agree to participate in the study<br><br> - adult patients (aged more than 18 years old)<br><br>Exclusion Criteria:<br><br> - previous treatment with check point inhibitor
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method development or increase level of anti-nuclear antibody;development or increase level of anti-cyclic citrullinated peptide antibodies;development or increase level of rheumatoid factor;development or increase level of Anti-glutamic acid decarboxylase antibodies;development or increase level of Anti-thyroperoxydase antibodies;development or increase level of Auto-antibodies associated with myositis
- Secondary Outcome Measures
Name Time Method